# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $7 to $5.
JMP Securities analyst Silvan Tuerkcan reiterates Notable Labs (NASDAQ:NTBL) with a Market Outperform and maintains $9 price...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $9 to $7.
The company presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patient...